MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
Patent Owner
Stats
- 28 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Sep 20, 2016 most recent publication
Details
- 28 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,523 Total Citation Count
- Aug 19, 1981 Earliest Filing
- 79 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9447166 Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptorsMar 31, 14Sep 20, 16[A61K, C07H, A01K, C07K]
8435947 Endothelial nitric oxide synthase antagonists and uses thereof for inhibiting oxygen toxicityMay 09, 11May 07, 13[A61K]
8309534 Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancerMay 15, 08Nov 13, 12[A61K, A01N]
8211864 Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptorsJan 26, 06Jul 03, 12[A61K, C07H, C12N]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0152,413 Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double Stranded RNAAbandonedSep 05, 14Jun 04, 15[C12N]
2012/0288,472 REGULATION OF T CELL-MEDIATED IMMUNITY BY TRYPTOPHANAbandonedMay 21, 12Nov 15, 12[A61K, A61P]
2012/0141,998 ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCEAbandonedFeb 15, 12Jun 07, 12[C12Q, G01N]
2012/0142,750 INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLSAbandonedNov 30, 11Jun 07, 12[A61K, A61P]
2011/0305,713 METHODS AND COMPOSITIONS TO ENHANCE VACCINE EFFICACY BY REPROGRAMMING REGULATORY T CELLSAbandonedApr 13, 11Dec 15, 11[A61K, C12N, A61P]
2011/0135,572 COMPOSITIONS AND METHODS FOR DIAGNOSING LATE-ONSET ALZHEIMER'S DISEASEAbandonedMay 28, 10Jun 09, 11[A61K, C12Q, C40B]
2011/0135,672 HLA-G COMPOSITIONS AND METHODS OF USE THEREOFAbandonedMay 27, 10Jun 09, 11[A61K, B82Y, C12N, A61P, C07K, B32B]
2011/0123,590 Selective Expansion of Regulatory T CellsAbandonedMay 17, 10May 26, 11[A61K, C12N, C12M]
2011/0124,678 TREATMENT WITH ALPHA 7-SELECTIVE LIGANDSAbandonedAug 01, 08May 26, 11[A61K, C07D, A61P]
2011/0124,720 COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERSAbandonedJan 05, 11May 26, 11[A61K, C07D, A61P]
2011/0047,631 HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCERAbandonedJan 08, 10Feb 24, 11[A61K, C12Q, C12N, G01N, A01K, A61P]
2010/0324,064 NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERSAbandonedJul 22, 10Dec 23, 10[A61K, C07D, C07C, A61P]
2010/0297,160 High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine AntigensAbandonedMay 14, 10Nov 25, 10[A61K, C12N, A61P]
2010/0287,627 Transgenic Zebrafish Models for Neurodegenerative DiseasesAbandonedDec 23, 09Nov 11, 10[A61K, A61P]
2010/0278,907 Immunogenic Compositions Containing Ceramide and Methods of Use ThereofAbandonedMay 12, 10Nov 04, 10[A61K, A61P]
2010/0266,588 Breast Cancer Susceptibility Gene GT198 and Uses ThereofAbandonedApr 20, 10Oct 21, 10[A61K, C12Q, A61P]
2010/0267,042 Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune ToleranceAbandonedApr 01, 10Oct 21, 10[C12Q, G01N]
2010/0212,038 TRANSGENIC FISH WITH TISSUE-SPECIFIC EXPRESSIONAbandonedJan 16, 09Aug 19, 10[C12Q, C12N, A01K]
2010/0111,943 COMPOSITIONS AND METHODS FOR INHIBITING CANCER METASTASISAbandonedMar 24, 08May 06, 10[A61K, C07H, C12N, C07K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
